response

Apa format

Respond to each peer and at least 2 references each

 

Peer 1

Lumbar Radiculopathy Assessment and Management

Patient Information:

JD, 42 years, Male, African-American.

S.

CC: "I've been experiencing pain in my lower back for the past month, and it sometimes radiates to my left leg."

HPI: A 42-year-old male presents with a one-month history of lower back pain that occasionally radiates to his left leg. The patient did not mention any recent injury, trauma, or significant precipitating event. Pain is described as constant and sharp, with an intensity of 6/10. Pain worsens with bending and lifting and is alleviated by rest and over-the-counter analgesics.

Current Medications: Over the counter NSAIDs for pain relief.

Allergies : No known drug allergies. Denies latex and environmental allergies.

PMHx: No known previous episodes of lower back pain. No history of chronic pain or spinal disorders. No previous surgeries. No significant medical history.

Soc Hx:Non-smoker, moderate alcohol consumption, sedentary job.

Fam Hx: The patient reports a family history of hypertension in his mother and father, and type 2 diabetes in his maternal uncle. There is no reported family history of spinal disorders or significant musculoskeletal issues.

ROS:

Vitals: BP 120/80 mmHg, HR 75 bpm, RR 16 bpm, Temp 98.6°F, SpO2 99%.

General: Alert, well-oriented, in mild discomfort due to pain.

HEENT: Normocephalic, atraumatic. PERRLA, EOMI. No lymphadenopathy or tenderness.

Neck: Supple, full range of motion, no vertebral tenderness.

Back: Paraspinal muscle tenderness in the lower back region, no visible deformity or swelling.

Neurological: Normal gait, normal strength in all extremities, sensation intact.

O.

Physical Exam:

General: The patient is alert, well-oriented, and in mild discomfort due to pain. He is well-groomed and appears to be in good general health.

Head: Normocephalic and atraumatic, no visible masses, depressions, or lesions.

EENT: Pupils equal, round, and reactive to light and accommodation (PERRLA). Extraocular movements intact (EOMI). Conjunctiva and sclera are clear. Tympanic membranes are intact, and nares are patent. No cervical lymphadenopathy or tenderness.

Neck: Supple, with full range of motion, no jugular venous distension (JVD), no carotid bruits, and no vertebral tenderness.

Chest: Respiratory effort is even and unlabored, with symmetric chest expansion. Breath sounds are clear to auscultation bilaterally, with no wheezing, rales, or rhonchi.

Cardiovascular: Heart rate is regular, with normal S1 and S2 heart sounds. No murmurs, rubs, or gallops are noted.

Abdomen: Soft, non-tender, and non-distended. Bowel sounds are present and normoactive in all quadrants. No hepatosplenomegaly or masses are palpable.

Back: Paraspinal muscle tenderness in the lower back region, no visible deformity or swelling. No costovertebral angle (CVA) tenderness.

Extremities: No edema, cyanosis, or clubbing. Peripheral pulses are 2+ and equal bilaterally in the upper and lower extremities.

Neurological: Alert, oriented to person, place, and time. Normal gait, normal strength in all extremities, sensation intact. Deep tendon reflexes are 2+ and equal bilaterally.

Diagnostic Results:

1. Lumbar spine X-ray: To assess for any bony abnormalities, fractures, or alignment issues. This imaging can provide preliminary information about potential issues with the lumbar spine (Kim et al., 2020).

2. Lumbar spine MRI: To visualize soft tissues, such as intervertebral discs, nerve roots, and spinal cord, to evaluate for herniated discs, nerve root compression, or other causes of lumbar radiculopathy. This imaging is essential for accurate diagnosis and treatment planning (Hansen et al., 2019).

3. CBC, CRP, and ESR: To rule out infection or inflammation as a contributing factor to the patient's lower back pain.

4. HbA1c: To evaluate the patient's blood sugar control, given the family history of type 2 diabetes.

A .

Primary Diagnosis:

Lumbar Radiculopathy: The patient's history of lower back pain radiating to the left leg, positive Straight Leg Raise test, and neurological findings suggest lumbar radiculopathy, possibly involving the L4, L5, and/or S1 nerve roots (Berry et al., 2019).

Differential Diagnoses:

1. Lumbar Strain or Sprain: The patient's pain could be due to muscle or ligament injury in the lower back, often resulting from overuse, poor posture, or lifting heavy objects (Pangarkar et al., 2019).

2. Lumbar Spinal Stenosis: The patient's symptoms may indicate spinal canal narrowing, which can compress nerve roots and cause pain or discomfort (Skelly et al., 2022).

3. Degenerative Disc Disease: Age-related wear and tear of intervertebral discs may lead to pain and discomfort in the lower back (Pangarkar et al., 2019).

4. Lumbar Spondylolisthesis: The patient's pain could be a result of one vertebra slipping forward over the vertebra below, causing nerve root compression (Skelly et al., 2022).

5. Infection or Inflammatory Disorder: Although less likely, the patient's pain could be due to an underlying infection or inflammation affecting the spine or nearby tissues (Pangarkar et al., 2019).

                               

Peer 2

pisodic/Focused SOAP Note

Patient Information: 

J.D., age 42, Male

S.

CC: “My back started hurting about a month ago and it radiates down my left leg sometimes.”

HPI: The patient is a 42-year-old male presents to the clinic with concerns about acute low back pain that started a month ago and that intermittently radiates down his left leg. He states that he works in construction and has to lift heavy daily. He states that he first noticed the pain after he and a coworker were lifting a piece of heavy machinery and his coworker slipped and the brunt of the object was forced onto the patient. He states that he did not feel any acute pain at the time of injury, and noticed a searing, hot pain in his lower back the following morning. He describes the pain at rest as a dull ache and with certain movements the pain is sharp and sudden. He states that when the pain radiates to his left leg it is localized to his posterior buttocks and thigh and does not extend past his knee. He states that when the shooting pain occurs his left leg becomes weaker, and he feels his left leg “buckle.” He states that the sharp pain occurs most frequently upon transfers from standing/sitting, hyperextending the spine, and with left and right spinal rotations. He states that pain feels relieved when he flexes his spine to relieve pressure from the lower lumbar and sacral regions. He states that he has been taking ibuprofen 800 mg twice daily upon awakening and at bedtime with mild relief of pain. He has tried using lidocaine patches without relief. He states that ice and heat seem to help alleviate the pain temporarily. He rates his pain at rest 3/10 and with exacerbating factors 8/10.

Current Medications:

· Lisinopril 10 mg PO daily

· Atorvastatin 10 mg PO daily

· Ibuprofen 800 mg PO BID PRN

· Lidocaine 5% topical patch daily PRN

Allergies: No known medical, food, or environmental allergies.

PMHx: Up to date on all current immunizations. Flu shot received for season via occupational RN at worksite. Last tetanus 12/10/2022. Hypertension and hyperlipidemia diagnosed 10 years ago. No major surgeries or hospitalizations.  Soc Hx: Construction worker since 18 years old. Never married and no children. In relationship with female for past 15 years. Enjoys hiking, biking, and playing various sports with girlfriend and friends on the weekends. Smokes 1 PPD since 18 years old. Denies illicit drug use. Drinks 5-6 beers on the weekends.

Fam Hx: Mother – HTN, HLD, CAD, OA – bilateral knees and hips s/p bilateral total knee replacements, age 61. Father – HTN, HLD, DM II, and DDD, age 64. Sister – HTN, age 40. Maternal grandmother – HTN, HLD, COPD, OA, CHF, died at 81 due to MI. Maternal grandfather – HTN, CAD, died at 78 due to stroke. Paternal grandmother – DM II, HTN, HLD, age 87. Paternal grandfather – HTN, COPD, CHF, died at 73 of acute complications from CHF.

ROS:

GENERAL:  No weight loss, fever, chills, or fatigue. Intermittent weakness in LLE.

HEENT:  Eyes:  No visual loss, blurred vision, double vision or yellow sclerae. Ears, Nose, Throat: No hearing loss, sneezing, congestion, runny nose, or sore throat.

SKIN:  No rash or itching. No discoloration or temperature changes to BLEs.

CARDIOVASCULAR:  No chest pain, chest pressure or chest discomfort. No palpitations or edema.

RESPIRATORY:  No shortness of breath, cough, or sputum.

GASTROINTESTINAL:  No anorexia, nausea, vomiting, constipation, or diarrhea. No abdominal pain or blood.

GENITOURINARY:  No painful urination.

NEUROLOGICAL:  No headache, dizziness, syncope, paralysis, or ataxia. Intermittent tingling in left posterior thigh and buttocks. No change in bowel or bladder control.

MUSCULOSKELETAL: Unrelenting dull ache in lower back. Intermittent sharp pain that radiates from lower back to LLE posterior thigh and buttocks.

HEMATOLOGIC:  No anemia, bleeding, or bruising.

LYMPHATICS:  No enlarged nodes. No history of splenectomy.

PSYCHIATRIC:  No history of depression or anxiety.

ENDOCRINOLOGIC:  No reports of sweating, cold or heat intolerance. No polyuria or polydipsia.

ALLERGIES:  No history of asthma, hives, eczema, or rhinitis.

O.

Physical exam:

Vital signs: BP 132/85, P 81, RR 18, SpO2 98%, Ht 6’3”, Wt 215 lbs BMI 26.9

General: Patient appears well-kempt.

HEENT:  Head: No tenderness reported.  Eyes: White sclera. Moist and pink conjunctiva. No conjunctival discharge.  Nose: Nasal cavities pink. Turbinates patent. No discharge.  Ears: Right auditory canal pink. No discharge. Right tympanic membrane pearly grey and cone of light at 5:00. Left auditory canal pink. No discharge. Left tympanic membrane pearly grey and cone of light at 7:00.  Mouth and throat: Oral mucosa moist and pink. Posterior oropharynx pink. No postnasal drip. Tonsils are not enlarged or erythemic.  Neck: Trachea midline. Non-palpable thyroid. No masses or tenderness.

Skin: Intact, warm to touch and dry. No scars noted. No discolorations noted.

Cardiovascular: S1 and S2 audible. No extra heart sounds. Capillary refill 2 seconds. Pulses 3+ throughout. No edema.

Respiratory: Symmetric chest. No visible abnormal findings to chest. Breath sounds present and clear in all areas. No adventitious breath sounds noted.

Gastrointestinal: Bowel sounds active throughout all 4 quadrants. No palpable masses. No tenderness reported. Bowel movements regular. No bloody stools. No changes in nutritional status.

Neurological: Alert and oriented. CN II-XII intact. Diminished sensation in left great toe.

Musculoskeletal: LLE ipsilateral leg pain at less than 60 degrees. Positive straight leg test. Positive heel walk test. Positive crossed leg raise test.

Hematological: No bruising noted.

Lymphatics: No palpable lymph notes noted.  

Psychiatric: Denies mood disorders. Denies changes in mood or behaviors. Appropriate mood, affect, and behaviors.

Endocrinological: No palpable masses to thyroid.

Diagnostic results:

1.) MRI – routine imaging utilized in the diagnosis of spinal diseases (Asma’a Al-Mnayyis et al., 2020; Casiano et al., 2019).

A .

Differential Diagnoses:

· L5 disk herniation – demonstrated by intermittent paresthesia to LLE posterior thigh, ipsilateral leg pain, and buttocks and positive MRI findings (Casiano et al., 2019).

· Lumbosacral muscle sprain – ruled out via MRI imaging demonstrating lumbar disk herniation (Casiano et al., 2019).

· Spinal stenosis – ruled out via MRI imaging providing evidence that the lumbar spine is not narrowed, hence not the cause of the acute back pain (Katz et al., 2022).

· Vertebral compression fracture – ruled out via imaging demonstrating lumbar disk herniation (Casiano et al., 2019).

· Malignant tumor – ruled out via MRI imaging demonstrating no evidence of malignancies (Asma’a Al-Mnayyis et al., 2020).

This section is not required for the assignments in this course (NURS 6512) but will be required for future courses.

Peer 3

Generalized anxiety disorder (GAD) is a chronic condition of uncontrolled anxiety. The hallmark of GAD is excessive or unrealistic anxiety about everyday stress-related situations lasting longer than six months. These patients may exhibit nervousness, restlessness, difficulty concentrating, difficulty staying or falling asleep, excessive fatigue, headaches, difficulty swallowing, and excessive diaphoresis (Carl et al., 2019). Most patients have additional comorbidity of depression.  

Current pharmacological options for treating anxiety are serotonergic reuptake inhibitors (SSRI), serotonin-norepinephrine reuptake inhibitors (SNRI), non-benzodiazepine-nonbarbiturates, and benzodiazepines. Both have the adverse effects of nausea, headache, dry mouth, diarrhea, or constipation (Garakani et al., 2020). The first line treatment for GAD, SSRIs are the three antidepressants duloxetine, paroxetine, and escitalopram. These medications are administered to patients who also have depression. These medications continually work on anxiety and depression even when depression is not present. SNRI venlafaxine has been used in short-term and long-term depressive and anxious episodes. Recommended duration of treatment can be as short as three to six months or up to one to two years.

 Non-benzodiazepine-non barbiturate medication Buspirone is an anxiolytic drug used for GAD, panic disorder, obsessive-compulsive disorder, social anxiety disorder, and episodes of PTSD. Buspirone does not possess any depressant or addictive properties and can be used as a short-term option without any psychomotor slowing. It can be used alone or in conjunction with an SSRI or SNRI. It has been known to be well tolerated without nausea or dizziness. Gradual onset of action is around ten days to four weeks; adverse effects include headache, movement disorders, and occasional sexual dysfunction.

Many in the field of anxiety disorders are reviewing the use of cannabis-based medical products. Many feel that the use of SSRIs or benzodiazepines causes refractory anxiety, side effects, and an increase in therapeutic doses over time. The endocannabinoid system is an endogenous system of neurotransmitters, enzymes, and cannabinoid receptors and has shown preclinical success for GAD. A recent study reviewed using cannabis-based Medicinal products (CBMP) in patients with generalized GAD. It showed a significant improvement in anxiety outcomes compared to those using an SSRI. The study revealed side effects of dry mouth and occasional paranoia; however, most patients reported improved sleep quality, anxiety episodes, and concentration (Ergisi et al., 2022).

Consider factors that might have influenced the patient's pharmacokinetic and pharmacodynamic processes.

The Pharmacokinetics that could affect the movement of SSRIs and SNRIs in the body could differ depending on the type of drug utilized. Each medication has a different half-life and differences in potency and efficacy. When prescribing an SSRI, a clinician must determine the half-life, extended half-life, and potential safety risks depending on the patient's compliance and comorbidities. For example, of the SSRIs mentioned, the half-life of paroxetine and escitalopram is 21 to 36 hours. These drugs have an extensive metabolism with high inter-individual variability, resulting in variable blood concentrations in differing patients (Hiemke & Härtter, 2000).

The pharmacodynamic processes of SSRIs Must be strictly scrutinized depending on the individual patient. SSRIs are metabolized by CYP 2D6, which displays sizeable individual-to-individual variability depending on the patient's genetic makeup. Some patients possess the alleles that account for poor metabolization of SSRIs. Genetic evaluation can be done for the CYP2D6 genotype testing. SSRIs have a black box warning for increased risk of suicide among pediatric and young adults. SSRIs are contraindicated with the concurrent use of MAOIs, which can increase the risk for life-threatening serotonin syndrome. Paroxetine is contraindicated in pregnancy due to its teratogenic effects. All patients under 25 should be continually assessed for suicidal ideation. For patients with cardiac risk factors, an EKG must be done in QT prolongation, and arrhythmias must be monitored. In the elderly neuronal and neurotransmission changes have been reported due to increased sensitivity. White matter hyperintensities are shown to be more probable in the elderly leading to chronic depression and lesser response to antidepressant therapy. The elderly have a higher risk for comorbidity. Lastly, elderly patients can come from difficult social situations and factors that may hinder the facilitation of adequate medication distribution (Gutsmiedl et al., 2020). An increase in suicidal ideation has been found in adults with additional insomnia symptoms. African American and Hispanic patients taking SSRIs with drugs or alcohol have an increased risk of suicidal ideation. Studies have shown that women are slightly less likely than men to develop suicidal ideation and tend to build them later in care (Edinoff et al., 2021).

Think about a personalized plan of care based on these influencing factors and the patient history with GAD.

A personalized care plan would be developed for an elderly patient with generalized anxiety disorder and chronic kidney disease. The prevalence of anxiety and depression in patients with chronic kidney disease is between 21 and 34%. In chronic kidney disease, the protein binding ability of the psychotropic drugs is decreased. The unbound forms of the medication are responsible for the therapeutic effect, and dosing adjustment needs to be made depending on the level of renal impairment. The clinician, in this case, would be prudent to prescribe the SSRI fluoxetine, as the level of the drug in the system remains unchanged irrespective of the severity of the renal impairment. All other SSRI excretion is affected by renal impairment. And in severe renal impairment, the concentration of these medications may increase up to 50%, requiring a lower-than-normal dosage.

Additionally, for acute episodes of anxiety, Benzodiazepines can be used with caution as they may accumulate in renal impairment, causing excessive sedation (Kar et al., 2022). Therefore, in the case of an elderly patient with GAD and CKD, the patient would be prescribed fluoxetine 20 milligrams PO QAM and may increase the dose after several weeks, depending on the symptoms. The patient would be educated on the severe reactions of suicidal ideation, mania, anaphylaxis, Stevens-Johnson syndrome, vasculitis, pulmonary fibrosis, and extrapyramidal syndrome. They would additionally be educated on the possible common reactions of nausea, headache, diarrhea, and sexual issues such as libido decrease, ejaculatory dysfunction, impotence, and weight loss. Patients would be continuously monitored for suicidal ideation, clinical worsening of behavior, or changes to anxiety, especially during the initial treatment.

Pharmacokinetics and pharmacodynamics are related to anxiolytic medications used to treat GAD.

Anxiolytic medications used to treat GAD are benzodiazepines such as diazepam and clonazepam. The Pharmacokinetics of benzodiazepines are typically from oral administration, well absorbed in the gastrointestinal tract, and their active metabolites to plasma proteins. And the concentration in the cerebral spinal fluid is approximately equal to the expected concentration of free drugs in the plasma. It metabolizes in forming N-des alkylated metabolites that are biologically active and excreted by the kidney. Half-life is highly increased in the elderly and patients with renal dysfunction.

The pharmacodynamics of benzodiazepines used for GAD are minimally affected by hepatic impairment. Patients with renal impairment have decreased clearance in plasma binding, increasing half-life. Lorazepam is the safest empiric dosing. Benzodiazepines are classified as indicative of fetal risk in pregnant patients and can be used cautiously in breastfeeding patients (Bounds & Nelson, 2023).

Peer 4

Generalized anxiety disorder is a chronic illness that affects 5% of all children, and 3-6% of all adults. This anxiety disorder usually begins during adolescence to early adulthood and likely will follow them throughout their lifespan. Generalized anxiety disorder is typically characterized by an unwelcome, widely spread anxiety related to multiple causes. GAD and other Anxiety related disorders are very commonly seen in the healthcare setting (Mayo Foundation, 2017). In my experience, it is the most common patient history factor seen in general. Therefore, it is important to understand the proper treatment for these patients and the different options available to them. I will discuss pharmacokinetics and pharmacodynamics related to anxiolytic medications used to treat GAD. Also, compare different treatment options.

For less severe cases, treatment can be in a non-pharmacologic form. However, in more severe cases where generalized anxiety affects a patient's daily routine, medications can be recommended. Certain medications can be prescribed depending on the severity of the patient's anxiety. Psychopharmacologic treatment of general anxiety disorder requires a provider to consider a patient’s age, co-morbidities, and previous treatments prescribed, and their outcomes (Mayo Foundation, 2017).

A first line medication is either an SSRI or SNRI for adults, and for pediatric patients the first line treatment is an SSRI only.  These medications are meant to be used daily, long term. SSRI’s are considered to have broad spectrum efficiency in short and long term treatments and are generally well tolerated by all patients. The FDA approved Lexapro and Paxil (SSRI’s) as indicated drugs for generalized anxiety, as well as Cymbalta and Effexor (SNRI’s). Benzodiazepines are a second-line choice medication and should be reserved for patients who have acute panic attacks, or for patients who have failed CBT therapy and other medication issues. Xanax and Klonopin are FDA approved Benzodiazepines for general anxiety disorder (Food and Drug Administration, 2014). They become effective almost immediately due to being easily absorbed) However, they are not meant to be used long term due to their withdraw reactions.

These medications are generally well tolerated except in the elderly population. The elderly population can experience an increase in side effects and toxicity (Strawn et al., 2018). The pharmacokinetics and pharmacodynamics differences between different antidepressants include their half-life, discontinuation of therapy, and potential drug interactions. Other factors to be considered are a patient’s genetic predisposition, brain chemistry, and life experiences.

The half-life of anxiety medications should be considered before being prescribed. In some patients it is more favorable to have a sustained half-life, because a slower rate of elimination lessens withdraw risks. Patients with hepatic dysfunction and inability to metabolize drugs properly. Some SSRIs have a half-life of a few hours while others take several days (Magellan RX Management, 2021).

One of the anxiolytic classes used in the treatment of GAD is selective serotonin reuptake inhibitors (SSRIs). These medications function by inhibiting serotonin or 5-hydroxytryptamine (5-HT) reuptake transporter. As a result, the neurotransmitter's concentrations in the synapses rise substantially, increasing extra-synaptic diffusion. Examples of SSRIs include fluoxetine, sertraline, paroxetine, and citalopram (Strawn et al., 2018). These drugs differ in selectivity and potency for the 5-HT transporter. They also possess distinct interaction capabilities with other extra and synaptic receptors. These aspects extend to their different side effects and efficacy profiles. Selective serotonin-norepinephrine reuptake inhibitors (SNRI) treat GAD by inhibiting norepinephrine and serotonin transporters.

Gamma-aminobutyric acid (GABA)-A agonists such as benzodiazepines are other classes of anxiolytics. These medications elicit positively modulate GABA-A receptors allosterically, potentiating the effects of the endogenous GABA after binding. Multimodal antidepressants like vortioxetine act by inhibiting the 5-HT7transporter and the 5-HT1D receptor (Strawn et al., 2018). Similarly, atypical antidepressants such as vilazodone act through serotonin transporter inhibition and partial 5-HT1A receptor agonism. On the other hand, mirtazapine PK is evident upon pre-synaptic alpha-2-adrenergic auto receptor inhibition with an affinity for 5-HT2C and 5-HT2A.

Genetic understanding is still in its early phases, but there is a clear understanding that there is a genetic predisposition link. If the patient has a first degree relative with GAD, patients are more likely to develop mood and anxiety disorders. Women are also 2x more likely to develop an anxiety disorder than men.  Diagnostic scans and autopsy evaluations of the brain have linked generalized anxiety disorder to abnormalities in the brain structures. Elevated activity in the amygdala is noted in patients with anxiety disorders, as well as increased amounts of gray matter in certain areas of the brain (in the right putamen specifically) (Strawn et al., 2018).

Therefore, when prescribing these medications, subtle changes in drug therapy must be made to find a therapeutic dose. Keeping in mind patients’ current drug regimen and history will be important as well.